Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Cell ; 23(2): 238-48, 2013 Feb 11.
Article in English | MEDLINE | ID: mdl-23410976

ABSTRACT

Significant endeavor has been applied to identify functional therapeutic targets in glioblastoma (GBM) to halt the growth of this aggressive cancer. We show that the receptor tyrosine kinase EphA3 is frequently overexpressed in GBM and, in particular, in the most aggressive mesenchymal subtype. Importantly, EphA3 is highly expressed on the tumor-initiating cell population in glioma and appears critically involved in maintaining tumor cells in a less differentiated state by modulating mitogen-activated protein kinase signaling. EphA3 knockdown or depletion of EphA3-positive tumor cells reduced tumorigenic potential to a degree comparable to treatment with a therapeutic radiolabelled EphA3-specific monoclonal antibody. These results identify EphA3 as a functional, targetable receptor in GBM.


Subject(s)
Brain Neoplasms/prevention & control , Glioblastoma/prevention & control , Mitogen-Activated Protein Kinases/metabolism , Neoplastic Stem Cells/pathology , Receptor Protein-Tyrosine Kinases/metabolism , Animals , Antibodies, Monoclonal/pharmacology , Apoptosis , Blotting, Western , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Cell Differentiation , Cell Proliferation , Flow Cytometry , Fluorescent Antibody Technique , Glioblastoma/genetics , Glioblastoma/pathology , Humans , Immunoprecipitation , Mice , Mice, Inbred NOD , Mice, SCID , RNA, Small Interfering/genetics , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/genetics , Receptor, EphA3 , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...